BioPharma Dive |
Glaxos Eosinophilic Asthma Drug Nucala Wins CHMP Backing
Zacks.com In the U.S., the drug is approved for both COPD and asthma. We note that Glaxo has a collaboration agreement with Theravance for Relvar/Breo Ellipta and Anoro Ellipta (COPD). Relvar/Breo Ellipta generated sales of £94 million in the first half of 2015. After bad news on Breo, Glaxo's monthly asthma drug wins an EU rec |
View full post on asthma – Google News